Dr. Lin is a Physician-Scientist and Radiation Oncologist who specializes in thoracic malignancies. His laboratory is committed to developing approaches that will enhance traditional cancer therapies. They have developed a novel radiation sensitizer screen approach to identify in a high throughput manner targeted therapies that could immediately be translated to the clinical setting. Through this effort, two phase I clinical trials have been launched and accruing as a direct result of this research. Dr. Lin continues to apply novel approaches to identify other drivers of treatment resistance, and seek innovative strategies to counterbalance the resistance mechanisms. He is applying candidate gene knockdown or knockout screens to identify immunomodulators or radiation sensitivity modulators. The focus is on clinical translation, taking potential drug candidates and testing them in preclinical studies to validate the utility of combining radiation sensitizers or immunomodulators with standard of care chemoradiotherapy or radiotherapy alone approaches for the management of lung and esophageal cancer. Promising agents are brought to the clinic as investigator-initiated trials.